Literature DB >> 16675226

Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats.

Haiwei Wu1, Binhui Ren, Jiaquan Zhu, Guohua Dong, Biao Xu, Changtian Wang, Xiaogang Zheng, Hua Jing.   

Abstract

OBJECTIVE: Based on the findings that erythropoietin (EPO) has been proved to be a multiple functional cytokine to attenuate ischemia-reperfusion (I/R) injury in various organs such as brain, heart, and kidney in animals, this experiment was designed to evaluate the effect of pretreatment with recombined human erythropoietin (rhEPO) on I/R-induced lung injury.
METHODS: Left lungs of rats underwent 90 min of ischemia and then were reperfused for up to 2 h. Animals were randomly divided into three experimental groups as sham group, I/R group, and rhEPO + I/R group (a single dose of rhEPO was injected intraperitoneally 3000 U/kg 24 h prior to operation). Lung injury was evaluated according to semi-quantitative analysis of microscopic changes, tissue polymorphonuclear neutrophils (PMNs) accumulation (myeloperoxidase (MPO) activity), and pulmonary microvascular permeability (Evan's blue dying method). Peripheral arterial and venous blood samples were obtained for blood-gas analysis after 5 min occlusion of right lung hilus at the end of reperfusion. The serum concentration of tumor necrosis factor (TNF)-alpha was also measured by the method of enzyme-linked immunosorbent assay.
RESULTS: Histological injury scoring revealed significantly lessened lung alveolus edema and neutrophils infiltration in the rhEPO pretreated group compared with I/R group (p < 0.05). The rhEPO pretreated animals exhibited markedly decreased lung microvascular permeability (p < 0.05) and myeloperoxidase activity (p < 0.05). Blood-gas analysis demonstrated that the pretreated animals had significantly ameliorated pulmonary oxygenation function (p < 0.05). The serum concentration of tumor necrosis factor-alpha in rhEPO pretreated group was markedly decreased compared with that of I/R group (p < 0.05).
CONCLUSIONS: Pretreatment with rhEPO appears to attenuate I/R-induced lung injury. This function is partly related with the capacity that rhEPO inhibits the accumulation of polymorphonuclear neutrophils in lung tissue and decreases the systematic expression of tumor necrosis factor-alpha.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675226     DOI: 10.1016/j.ejcts.2006.02.036

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  25 in total

1.  Erythropoietin Treatment Ameliorates Lupus Nephritis of MRL/lpr Mice.

Authors:  Zeming Zhang; Dongmei Liu; Xiaoli Zhang; Xiaofei Wang
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

2.  A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

Authors:  Nimesh S A Patel; Kiran K Nandra; Michael Brines; Massimo Collino; Ws Fred Wong; Amar Kapoor; Elisa Benetti; Fera Y Goh; Roberto Fantozzi; Anthony Cerami; Christoph Thiemermann
Journal:  Mol Med       Date:  2011-05-13       Impact factor: 6.354

3.  Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats.

Authors:  Ensari Guneli; Zahide Cavdar; Huray Islekel; Sulen Sarioglu; Serhat Erbayraktar; Muge Kiray; Selman Sokmen; Osman Yilmaz; Necati Gokmen
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

Review 4.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

5.  Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Authors:  Michael Brines; Nimesh S A Patel; Pia Villa; Courtenay Brines; Tiziana Mennini; Massimiliano De Paola; Zubeyde Erbayraktar; Serhat Erbayraktar; Bruno Sepodes; Christoph Thiemermann; Pietro Ghezzi; Michael Yamin; Carla C Hand; Qiao-wen Xie; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-01       Impact factor: 11.205

Review 6.  Raves and risks for erythropoietin.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang
Journal:  Cytokine Growth Factor Rev       Date:  2008-03-04       Impact factor: 7.638

Review 7.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

Review 8.  Erythropoietin and oxidative stress.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Curr Neurovasc Res       Date:  2008-05       Impact factor: 1.990

9.  Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis.

Authors:  Oge Tascilar; Güldeniz Karadeniz Cakmak; Ishak Ozel Tekin; Ali Ugur Emre; Bulent Hamdi Ucan; Burak Bahadir; Serefden Acikgoz; Oktay Irkorucu; Kemal Karakaya; Hakan Balbaloglu; Gurkan Kertis; Handan Ankarali; Mustafa Comert
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.